Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Isis Begins Phase II Program for Cholesterol Drug | Contract Pharma

What are you searching for?

Sign in

Isis Begins Phase II Program for Cholesterol Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Isis Pharmaceuticals has initiated the development program of ISIS 301012 in patients with familial hypercholesterolemia (FH), a genetic disorder that causes extremely high cholesterol levels and results in the early onset of heart disease. ISIS 301012, a second-generation antisense drug, reduces levels of apoB-100, a protein critical to the synthesis and transport of the “bad” cholesterol involved in heart disease—low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein (VLDL). Lowering cholesterol levels is a key component in the prevention and management of cardiovascular disease.

The Phase II studies will evaluate the safety and efficacy of ISIS 301012 in patients with FH who are not achieving their cholesterol target levels on lipid-lowering therapy. In the studies, patients will be dosed with 50 mg, 100 mg or 200 mg of ISIS 301012 for six weeks treatment period and then followed for five months.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters